# The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC

> **NCT04877821** · PHASE2 · COMPLETED · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 29 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Anlotinib
- **DRUG:** Nab paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT04877821
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-15
- **Primary completion:** 2023-08-31
- **Final completion:** 2026-03-10
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04877821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04877821, "The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04877821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*